Saturday 17 October 2026
Export BBIO’s income statement to Excel — free account
BridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024. In the quarter to June 2026, revenue grew 120.4%, EPS grew 17.9%, free cash flow grew 16.6% and total debt rose 4.22%, each against the same quarter a year earlier.
66.39
0.74
−1.10%
Follow BBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
28.17 | 29.18 | 24.94 | 20.45 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(90.94) | (259.66) | (73.32) | (205.09) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
31.58 | 31.71 | 26.65 | 22.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(19.11) | (35.70) | (34.81) | (36.36) | |
EV/FCF |
(18.69) | (34.94) | (34.07) | (35.58) | |
Quick Ratio |
3.52 | 2.52 | 1.40 | 1.09 | |
Current Ratio |
3.88 | 2.77 | 1.52 | 1.23 | |
Net Debt/EBITDA |
(8.21) | (9.57) | (9.58) | (11.60) | |
Debt/Assets |
185.43% | 197.91% | 140.49% | 158.35% | |
Debt/Equity |
(0.96) | (0.89) | (0.85) | (0.77) | |
Asset Turnover |
0.43 | 0.54 | 0.51 | 0.62 | |
Operating CF/Net income |
0.60 | 0.29 | 1.20 | 0.47 | |
Capex/Depreciation |
1.73 | 0.00 | (0.02) | (0.15) | |
Interest Coverage |
(3.02) | (2.77) | (2.01) | (1.96) | |
Research and Development Expense of Revenue |
93.52% | 75.51% | 65.10% | 61.33% | |
Selling, General and Administrative Expense of Revenue |
114.02% | 102.53% | 84.26% | 76.44% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
29.21% | 22.47% | 17.09% | 18.09% | |
Graham Net Nets |
(0.21) | (0.15) | (0.17) | (0.18) | |
Graham Number |
30.70 | 30.36 | 31.30 | 32.06 | |
Earnings Yield |
(8.05%) | (4.94%) | (5.04%) | (4.79%) | |
Free Cash Flow Yield |
(6.00%) | (3.11%) | (3.14%) | (3.04%) | |
Revenue per Share |
0.63 | 0.81 | 1.00 | 1.24 | |
Operating CF per Share |
(0.57) | (0.29) | (1.01) | (0.36) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.59) | (0.29) | (1.01) | (0.37) | |
Cash per Share |
3.37 | 3.07 | 4.83 | 3.68 | |
Shareholders Equity per Share |
(10.02) | (10.84) | (11.64) | (12.79) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(10.02) | (10.84) | (11.64) | (12.79) | |
Free Cash Flow |
(112.44) | (56.45) | (197.35) | (71.54) | |
Working Capital |
622.78 | 509.78 | 424.93 | 202.49 | |
Capital Expenditures |
(2.87) | (0.03) | (0.07) | (0.44) | |
Net Current Asset Value |
(2,081.62) | (2,214.29) | (2,397.60) | (2,629.04) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
58.50 | 72.08 | 160.25 | 165.68 | |
Average Payables |
16.03 | 22.92 | 28.29 | 26.67 | |
Average Inventory |
— | — | 18.47 | 35.56 | |
Average Assets |
831.61 | 927.68 | 1,126.31 | 1,148.74 | |
Average Common Equity |
(1,570.89) | (1,766.88) | (1,953.18) | (2,141.42) |
Columns are period end dates